You are here

Novartis signals growing ambitions for cancer therapies

Drugmaker is planning to test its CAR-T treatments on lethal cancers of the brain, pancreas, colon, ovary and lung

BT_20170131_SYNOV31_2716260.jpg
Novartis, which invested about US$9 billion last year in research and development, is trying to catch-up with rivals including Merck & Co and Roche Holding AG in cancer immunotherapies.

London

NOVARTIS AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumour-ridden patients.

Europe's second-biggest drugmaker is planning to test

sentifi.com

Market voices on:

Powered by GET.comGetCom